Medical therapy of paediatric inflammatory bowel disease

Antibodies targeting tumour necrosis factor have substantially advanced the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis than in Crohn's disease, highlighting the need for alternative biologic agents and oral small molecules.

Automated summary

Antibodies targeting tumour necrosis factor have improved the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis, emphasizing the need for alternative biologic agents and oral small molecules.